Purdue Pharma, the producer of OxyContin, recently announced it would end physician-directed marketing of all opioids. The move is a step forward in efforts to control misuse and abuse of opioids in the U.S., but, according to physicians in Maine, it comes two decades too late.
"They're 20 years late to the game," said Noah Nesin, MD, a family physician and vice president of medical affairs at Penobscot Community Health Care in Bangor, Maine, to NPR.
A Feb. 13 story from NPR, Maine Public Radio and Kaiser Health News explores what impact, if any, the drug-maker’s change in approach will have on public health.
Read more at the link below: